Cargando…
Ginsenoside Rh2 inhibits hepatocellular carcinoma through β-catenin and autophagy
Hepatocellular carcinoma (HCC) is the most common liver cancer, with a very poor prognosis. There is an urgent need for an effective therapy for HCC. Ginsenoside Rh2 (GRh2) has been shown to significantly inhibit growth of some types of cancer, whereas its effects on HCC have not been examined. Here...
Autores principales: | Yang, Zhiqing, Zhao, Tingting, Liu, Hongli, Zhang, Leida |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725994/ https://www.ncbi.nlm.nih.gov/pubmed/26783250 http://dx.doi.org/10.1038/srep19383 |
Ejemplares similares
-
Ginsenoside Rh2 activates α-catenin phosphorylation to inhibit lung cancer cell proliferation and invasion
por: Zhang, Guodong, et al.
Publicado: (2020) -
The interaction of serum albumin with ginsenoside Rh2 resulted in the downregulation of ginsenoside Rh2 cytotoxicity
por: Lin, Yingjia, et al.
Publicado: (2017) -
A novel autophagy activator ginsenoside Rh2 enhances the efficacy of immunogenic chemotherapy
por: Yang, Jing, et al.
Publicado: (2023) -
Ginsenoside Rh4 Inhibits Colorectal Cancer Cell Proliferation by Inducing Ferroptosis via Autophagy Activation
por: Wu, Yingchao, et al.
Publicado: (2022) -
Biotransformation of Ginsenoside Rf to Rh(1) by Recombinant β-Glucosidase
por: Ruan, Chang-Chun, et al.
Publicado: (2009)